Kidney cancer biostatistics and bioinformatics support core
Official title: DF/HCC Kidney Cancer Biostatistics and Bioinformatics Core 1
Funded at Beth Israel Deaconess Medical Center · NIH-11421796 · Data updated 2026-11-12
A dedicated biostatistics and bioinformatics core provides expert design, data management, and analysis support for kidney cancer research projects at a leading cancer center.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 18, 2003 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $322,233 |
| NIH project number | 2P50CA101942-21A1 |
| Project ID | NIH-11421796 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable as this is a core support grant and does not enroll patients directly; it supports research that may later involve patients through SPORE projects.
✕Less likely to help
Patients would not participate in the core activities themselves, as this grant funds the supporting analysis and data management infrastructure.
What this research studies
This grant funds a core facility that helps plan studies, manage data, and analyze results across kidney cancer projects, including laboratory, genomic, translational, clinical, and epidemiological work. It ensures data quality, proper storage, and transparent reporting while aligning with FAIR data practices. Researchers can access short-term statistical and bioinformatic consulting to strengthen study design and interpretation, improving the rigor and impact of kidney cancer science.
Why it matters
Potential benefit: If successful, patients could benefit from more rigorously designed kidney cancer studies and faster translation of findings into better diagnostics and treatments.
How similar studies have gone: Biostatistics and bioinformatics cores are standard in cancer centers and have a track record of improving study quality and reproducibility.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Xie, Wanling — Beth Israel Deaconess Medical Center
- Study coordinator: Xie, Wanling
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.